• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Notes

No. Proposition For Against Abstain
1

Election of Director to serve until Tevas 2027 Annual Meeting: Chen Lichtenstein

2

Election of Director to serve until Tevas 2028 Annual Meeting: Amir Elstein

3

Election of Director to serve until Tevas 2028 Annual Meeting: Roberto A. Mignone

4

Election of Director to serve until Tevas 2028 Annual Meeting: Dr. Perry D. Nisen

5

Election of Director to serve until Tevas 2028 Annual Meeting: Dr. Tal Zaks

6

To approve, on a non-binding advisory basis, the compensation for Tevas named executive officers

7

To approve an amended compensation policy with respect to the terms of office and employment of Tevas executive officers and directors

8

To approve an amendment to the terms of office and employment of Tevas president and chief executive officer

9

To approve the compensation to be provided to Tevas non- employee directors

10

To approve the compensation to be provided to Tevas non- executive chairman of the board

11

To appoint, Kesselman & Kesselman, a member of PriceWaterhouseCoopers International Ltd., as Tevas independent registered public accounting firm until Tevas 2026 annual meeting of shareholders.